Xeris Announces Board Changes Xeris Biopharma Holdings, Inc., a growth-oriented biopharmaceutical company dedicated to enhancing patient care through the development and commercialization of innovative therapies, has announced significant changes to its board of directors. These changes come as part of…
Equillium Announces Q4 & Full-Year 2024 Results, Corporate & Clinical Updates Equillium, Inc., a clinical-stage biotechnology company specializing in immunobiology, has reported its financial results for the fourth quarter and full year 2024, alongside recent corporate and clinical developments. The…
Havah Therapeutics Files Patent for HAV-088 in Breast Cancer Treatment Havah Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies for the prevention and treatment of breast cancer, has announced the filing of a new provisional patent application for…
Alcon Acquires Majority Stake in Aurion Biotech to Advance Corneal Cell Therapy Alcon, a global leader in eye care, has announced the acquisition of a majority interest in Aurion Biotech, Inc., a clinical-stage company specializing in advanced cell therapies for…
Epicrispr Biotech Raises $68M for FSHD Epigenetic Therapy Trial Epicrispr Biotechnologies, a pioneering biotechnology company dedicated to developing curative therapies, has announced the successful first close of its Series B financing, securing $68 million. The funds will be used to…
RenovoRx TAMP™ Pre-Clinical Results to Be Awarded at SIR 2025 RenovoRx, Inc. (“RenovoRx” or the “Company”), a pioneering life sciences company dedicated to advancing targeted oncology therapies, is pleased to announce that its research supporting the Company’s proprietary Trans-Arterial Micro-Perfusion…
Merck Licenses HRS-5346 for Cardiovascular Disease from Hengrui Merck, known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma”), a leading global pharmaceutical company with a strong focus on scientific and technological…
Xcell Biosciences Partners with Planet Innovation and Royal Perth Hospital to Advance Cell Therapy Manufacturing Xcell Biosciences Australia Pty Ltd (Xcellbio), a subsidiary of the San Francisco-based biotechnology company specializing in instrumentation for cell and gene therapy applications, has announced…
Veracyte’s Whole-Genome Sequencing-Based MRD Test Shows High Accuracy for Muscle-Invasive Bladder Cancer Detection Veracyte, Inc., a leader in cancer diagnostics, has announced groundbreaking new data demonstrating the accuracy and effectiveness of its whole-genome sequencing (WGS)-based minimal residual disease (MRD) testing…
Dr. Mike Graham Named Head of R&D at Bayer Crop Science Bayer has officially announced that Dr. Mike Graham will assume the role of Head of Research & Development (R&D) for Bayer’s Crop Science division. In this capacity, he will…
CEL-SCI: Multikine Boosts Quality of Life by Up to 95% in Head & Neck Cancer Patients CEL-SCI Corporation (NYSE American: CVM) has recently announced the publication of new data from its Phase 3 study of Multikine* (Leukocyte Interleukin, Injection) in…
Neurogene Announces Q4 & Full-Year 2024 Results, Updates Neurogene Inc., a clinical-stage company dedicated to developing life-changing genetic medicines for patients and families affected by rare neurological diseases, has announced its fourth quarter and full-year 2024 financial results along with…